CRISPR Therapeutics CRSP US — Operating Loss Carryforwards Expiration Period

Similar metrics at other companies

AMLXMA — Operating Loss Carryforwards Expiration Period

5100.0%

SSNCForeign Net Operating Loss Carryforwards Expiration Period

506.50.0%

GCTNon-US — Operating loss carryforwards with no expiration date

$2.5M—

TMCUS — Operating Loss Carryforwards

$20.6M+11,032%

WWRUS — Operating Loss Carryforwards

$284M+1.5%

XPLUS — Operating Loss Carryforwards

$3.77M-29.5%

FAQ

What is CRISPR Therapeutics's US — operating loss carryforwards expiration period?

CRISPR Therapeutics (CRSP) reported US — operating loss carryforwards expiration period of 511.3 in Q4 2025.

What does US — operating loss carryforwards expiration period mean?

This metric represents the estimated timeframe or aggregate value of tax attributes available to offset future taxable income within the United States geographic segment. It serves as a critical indicator of the company's ability to shield future earnings from tax liabilities, which is particularly relevant for high-growth biotechnology firms with significant historical R&D expenditures. Monitoring this helps investors assess the potential for future tax-advantaged cash flows as the company transitions toward commercial profitability.